



P.17019/01/2021-PvPI
Indian Pharmacopoeia Commission
National Coordination Centre-Pharmacovigilance Programme of India
(Ministry of Health & Family Welfare, Govt. of India)

Email: pvpi.ipc@gov.in, lab.ipc@gov.in, Website: www.ipc.gov.in, Tel. No. 0120-2783400

Sector-23, Raj Nagar,
Ghaziabad-201002, U.P.
Dated: 28th December, 2021.

Monthly Drug Safety Alert

The preliminary analysis of Adverse Drug Reactions (ADRs) from the PvPI database reveals that the following suspected drug is associated with the ADR as given below.

Sl. No.	Suspected Drug	Indication	Adverse Drug Reaction
1.	Remdesivir	Broad spectrum antiviral medication. Restricted emergency use for treatment of patients with severe COVID-19.	Sinus Bradycardia

Healthcare Professionals, Patients/Consumers are advised to closely monitor the possibility of the above ADR associated with the use of above suspected drug. If such reaction is encountered, please report to the NCC-PvPI, IPC by filling of Suspected Adverse Drug Reactions Reporting Form/Medicines Side Effect Reporting Form for Consumer (<http://www.ipc.gov.in>), through Android Mobile App “**ADR PvPI App**” and **PvPIHelpline No. 1800-180-3024 (Toll Free)**.